AI English summary of an SEC filing — figures as filed
Zimmer Biomet ZBHZimmer Biomet said it entered into a 5-year unsecured revolving credit agreement for $1.5 billion on June 27, 2025, maturing on June 27, 2030, and that borrowings will be used for general corporate purposes.
Key points
AI summaryZimmer Biomet said it entered into a 5-year unsecured revolving credit agreement for $1.5 billion on June 27, 2025, maturing on June 27, 2030, and that borrowings will be used for general corporate purposes.
The company entered into an unsecured 364-Day revolving credit facility of $1.0 billion maturing on June 26, 2026. It said both agreements require it to keep its ratio of consolidated indebtedness to consolidated EBITDA at no greater than 4.5 to 1.0, which may increase to 5.0 to 1.0 in connection with a qualified material acquisition.
Zimmer Biomet said the 5-year credit agreement has 2 one-year extension options of 1 year each, exercisable at the company's discretion and subject to lender consent. It also said the agreement includes an uncommitted incremental feature allowing it to request an increase of up to $500.0 million.
Zimmer Biomet terminated its existing 5-year and 364-Day credit agreements on June 28, 2024, effective June 27, 2025. The company said that of approximately $50.7 million in total borrowings under the existing 5-year agreement, including principal, interest and fees, $50.0 million was repaid with borrowings under the new 5-year agreement and approximately $0.7 million was repaid with cash on hand.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Zimmer Biomet enters 5-year $1.5 billion unsecured revolving credit facility
Zimmer Biomet said it entered into a 5-year unsecured revolving credit agreement for $1.5 billion on June 27, 2025, maturing on June 27, 2030, and that borrowings will be used for general corporate purposes.
Source · Based on the filing body and exhibits
364-Day credit facilities $1.0 billion and financial covenants
The company entered into an unsecured 364-Day revolving credit facility of $1.0 billion maturing on June 26, 2026. It said both agreements require it to keep its ratio of consolidated indebtedness to consolidated EBITDA at no greater than 4.5 to 1.0, which may increase to 5.0 to 1.0 in connection with a qualified material acquisition.
Source · Based on the filing body and exhibits
5-year facility extension options and increase feature
Zimmer Biomet said the 5-year credit agreement has 2 one-year extension options of 1 year each, exercisable at the company's discretion and subject to lender consent. It also said the agreement includes an uncommitted incremental feature allowing it to request an increase of up to $500.0 million.
Source · Based on the filing body and exhibits
Termination of existing 2024 credit agreements and repayment of borrowings
Zimmer Biomet terminated its existing 5-year and 364-Day credit agreements on June 28, 2024, effective June 27, 2025. The company said that of approximately $50.7 million in total borrowings under the existing 5-year agreement, including principal, interest and fees, $50.0 million was repaid with borrowings under the new 5-year agreement and approximately $0.7 million was repaid with cash on hand.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…